BioSpace News Archive

Completed enrollment in pivotal Phase 3 ACCORDANCE trial; on track for topline data in mid-2019

Bluestar Alliance LLC and HoMedics announce the signing of a $165 million, five-year license agreement under the Brookstone brand.

AcelRx Pharmaceuticals, Inc. today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering.

Leap Therapeutics, Inc. today reported a business update and financial results for the third quarter ended September 30, 2018.

Seres Therapeutics, Inc. today announced that it will present at the Stifel 2018 Healthcare Conference in New York, NY on Tuesday, November 13th at 9:30 a.m. ET.

Aurinia Pharmaceuticals Inc. today announced its Chairman and CEO, Richard Glickman, will participate in two upcoming investor conferences.

First single inhaler triple therapy to be specifically indicated for COPD patients not adequately treated with dual bronchodilation

Omeros Corporation (Nasdaq: OMER) (“Omeros”) today announced the pricing of an offering of $210 million aggregate principal amount of its 6.25% Convertible Senior Notes due 2023 (the “Notes”) in a private offering (the “Offering”) to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933 (the “Securities Act”)

LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, today announced a partnership with Patient True Talk, a free patient-to-patient platform where patients and their caregivers can search for others with the same diagnosis or recommended treatment protocol to connect via email or phone.

Crescita Therapeutics Inc. (TSX: CTX) (Crescita or the Company), a commercial dermatology company with a portfolio of non-prescription skincare and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today reported its financial results for the third quarter ended September 30, 2018.